2016
Secondary Prophylaxis in Special Patient Populations
Reiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations. 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecondary prophylaxisRefractory ascitesVariceal bleedingSurvival benefitClinical nonrespondersClear precipitating eventProphylaxis of varicealBeta-blocker therapyBeta-blocker treatmentEndoscopic band ligationSpecial patient populationsAdvanced cirrhosisNSBB therapyVariceal rebleedingArterial hypotensionCirrhotic patientsFurther decompensationSerum creatinineBand ligationPatient populationProphylaxisHigh riskCurrent evidencePatientsAscites
2011
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis
Berzigotti A, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Groszmann RJ, Group T. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011, 54: 555-561. PMID: 21567436, PMCID: PMC3144991, DOI: 10.1002/hep.24418.Peer-Reviewed Original ResearchConceptsBody mass indexClinical decompensationPortal pressureBMI groupsNormal body mass indexRole of obesityChronic viral hepatitisIndependent risk factorSubset of patientsValuable therapeutic measureActuarial probabilityCompensated cirrhosisViral hepatitisAggressive courseIndependent predictorsMass indexRandomized trialsLiver functionPatient populationRisk factorsTherapeutic measuresStudy populationCirrhosisTreatment groupsPatients
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conference